Free tool
FAERS Monitor: Kyprolis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202714 or its brand name (Kyprolis, Carfilzomib). Reports on generic versions are filed under their own applications.
Reports
28,379
Serious
21,874
77% of reports
Hospitalization
9,498
Death reported
4,434
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma3,057
- off label use2,413
- death1,768
- thrombocytopenia1,551
- fatigue1,549
- pneumonia1,398
- pyrexia1,176
- diarrhoea1,135
- neutropenia1,127
- dyspnoea1,122
- anaemia1,119
- nausea1,095
- acute kidney injury874
- drug ineffective867
- asthenia724
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 16 |
| 2012 | 140 |
| 2013 | 317 |
| 2014 | 613 |
| 2015 | 2,140 |
| 2016 | 2,450 |
| 2017 | 3,231 |
| 2018 | 2,601 |
| 2019 | 2,025 |
| 2020 | 2,010 |
| 2021 | 2,289 |
| 2022 | 2,518 |
| 2023 | 2,854 |
| 2024 | 2,286 |
| 2025 | 1,940 |
| 2026 | 947 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,780 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 3,057 | 62.9 | 60.8 | 171,955 |
| thrombocytopeniaSignal | 1,551 | 10.4 | 9.9 | 13,070 |
| neutropeniaSignal | 1,127 | 6.2 | 5.8 | 4,886 |
| anaemiaSignal | 1,119 | 4.4 | 4.1 | 2,912 |
| acute kidney injurySignal | 874 | 4.3 | 4.0 | 2,173 |
| pneumoniaSignal | 1,398 | 3.2 | 3.0 | 2,149 |
| pyrexiaSignal | 1,176 | 2.5 | 2.4 | 1,095 |
| off label useSignal | 2,413 | 2.0 | 2.0 | 1,340 |
| death | 1,768 | 1.5 | 1.5 | 329 |
| fatigue | 1,549 | 1.5 | 1.4 | 246 |
| dyspnoea | 1,122 | 1.5 | 1.4 | 172 |
| asthenia | 724 | 1.4 | 1.3 | 94 |
| diarrhoea | 1,135 | 1.3 | 1.2 | 82 |
| nausea | 1,095 | 1.0 | 1.0 | 1 |
| drug ineffective | 867 | 0.5 | 0.5 | 498 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.